Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
About this study
ADRIATIC study explored the benefits of immune maintenance therapy after LS-SCLC radiotherapy and chemotherapy. In the presence of immunotherapy, is it necessary to increase the dosage of radiotherapy and can it further improve the efficacy? This study aims to explore the efficacy and safety of simultaneous integrated boost hyperfractionation radiotherapy combined with probiotics and Adalberg monoclonal antibody consolidation therapy for small cell lung cancer.
- Condition
- Limited Stage Small Cell Lung Cancer
- Tested
- Probiotics, concurrent Hyperfractionated Radiotherapy, Immunotherapy
- Sponsor
- Fudan University
Who can join
- Age
- 18 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 10
- Minimum age: 18 years
- Maximum age: 80 years
- Study condition: Limited Stage Small Cell Lung Cancer
- Sign written informed consent before implementing any experimental procedures;
- Age range: 18-80 years old;
- Pathological diagnosis of small cell lung cancer;
- Limited stage;
- ECOG PS 0-1；
- Receive ≤ 2 rounds of chemotherapy or chemotherapy plus immunotherapy;
- Expected survival time\>3 months;
Exclusion 5
- Progress after 2 induction treatments;
- Severe emphysema, interstitial changes in the lungs, COPD patients;
- Resting blood oxygen\<93;
- Have a history of other malignant tumors and have received chemotherapy in the past 3 years;
- History of chest radiotherapy;
Where
1 site, 1 recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact
-
Xingwen Fan
+86 13651669687 wenxingfan@126.com
Potential match only. Final eligibility is determined by the study team.